Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586261 · ClinicalTrials.gov registry record · NA
Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00586261: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT00586261 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586261, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Nitroglycerin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586261
The ClinicalTrials.gov registry entry for NCT00586261 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00586261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586261 about?
NCT00586261 is a clinical study titled "Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function". The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.
What is the current status of trial NCT00586261?
This trial is currently terminated. It is a NA study. The enrollment target is 36 participants. The study started on 2006-03. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00586261?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00586261?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.